ESPR
Price
$0.95
Change
+$0.02 (+2.15%)
Updated
Apr 23, 04:59 PM (EDT)
Capitalization
495.94M
19 days until earnings call
ZOMDF
Price
$0.05
Change
-$0.00 (-0.00%)
Updated
Apr 22 closing price
Capitalization
137.19M
Ad is loading...

ESPR vs ZOMDF

Header iconESPR vs ZOMDF Comparison
Open Charts ESPR vs ZOMDFBanner chart's image
Esperion Therapeutics
Price$0.95
Change+$0.02 (+2.15%)
Volume$63.55K
Capitalization495.94M
Zomedica
Price$0.05
Change-$0.00 (-0.00%)
Volume$2.9M
Capitalization137.19M
ESPR vs ZOMDF Comparison Chart
Loading...
ESPR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ZOMDF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ESPR vs. ZOMDF commentary
Apr 24, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ESPR is a Hold and ZOMDF is a StrongBuy.

Ad is loading...
COMPARISON
Comparison
Apr 24, 2025
Stock price -- (ESPR: $0.94 vs. ZOMDF: $0.05)
Brand notoriety: ESPR and ZOMDF are both not notable
ESPR represents the Pharmaceuticals: Other, while ZOMDF is part of the Medical Specialties industry
Current volume relative to the 65-day Moving Average: ESPR: 104% vs. ZOMDF: 10%
Market capitalization -- ESPR: $495.94M vs. ZOMDF: $137.19M
ESPR [@Pharmaceuticals: Other] is valued at $495.94M. ZOMDF’s [@Medical Specialties] market capitalization is $137.19M. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $77.48B to $0. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The average market capitalization across the [@Pharmaceuticals: Other] industry is $3.65B. The average market capitalization across the [@Medical Specialties] industry is $8.31B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ESPR’s FA Score shows that 0 FA rating(s) are green whileZOMDF’s FA Score has 1 green FA rating(s).

  • ESPR’s FA Score: 0 green, 5 red.
  • ZOMDF’s FA Score: 1 green, 4 red.
According to our system of comparison, both ESPR and ZOMDF are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ESPR’s TA Score shows that 4 TA indicator(s) are bullish while ZOMDF’s TA Score has 3 bullish TA indicator(s).

  • ESPR’s TA Score: 4 bullish, 4 bearish.
  • ZOMDF’s TA Score: 3 bullish, 1 bearish.
According to our system of comparison, ZOMDF is a better buy in the short-term than ESPR.

Price Growth

ESPR (@Pharmaceuticals: Other) experienced а -2.11% price change this week, while ZOMDF (@Medical Specialties) price change was +4.29% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +2.96%. For the same industry, the average monthly price growth was -6.07%, and the average quarterly price growth was -9.98%.

The average weekly price growth across all stocks in the @Medical Specialties industry was +3.05%. For the same industry, the average monthly price growth was -8.45%, and the average quarterly price growth was -3.85%.

Reported Earning Dates

ESPR is expected to report earnings on Aug 05, 2025.

Industries' Descriptions

@Pharmaceuticals: Other (+2.96% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

@Medical Specialties (+3.05% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ESPR($496M) has a higher market cap than ZOMDF($137M). ESPR (-57.741) and ZOMDF (-60.000) have similar YTD gains . ZOMDF has higher annual earnings (EBITDA): -11.94M vs. ESPR (-150.11M). ZOMDF has more cash in the bank: 106M vs. ESPR (82.2M). ZOMDF has less debt than ESPR: ZOMDF (1.75M) vs ESPR (266M). ESPR has higher revenues than ZOMDF: ESPR (116M) vs ZOMDF (24M).
ESPRZOMDFESPR / ZOMDF
Capitalization496M137M362%
EBITDA-150.11M-11.94M1,258%
Gain YTD-57.741-60.00096%
P/E RatioN/AN/A-
Revenue116M24M483%
Total Cash82.2M106M78%
Total Debt266M1.75M15,183%
FUNDAMENTALS RATINGS
ESPR vs ZOMDF: Fundamental Ratings
ESPR
ZOMDF
OUTLOOK RATING
1..100
503
VALUATION
overvalued / fair valued / undervalued
1..100
37
Fair valued
24
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9892
PRICE GROWTH RATING
1..100
9795
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5048

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ZOMDF's Valuation (24) in the Pharmaceuticals Major industry is in the same range as ESPR (37) in the Biotechnology industry. This means that ZOMDF’s stock grew similarly to ESPR’s over the last 12 months.

ZOMDF's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as ESPR (100) in the Biotechnology industry. This means that ZOMDF’s stock grew similarly to ESPR’s over the last 12 months.

ZOMDF's SMR Rating (92) in the Pharmaceuticals Major industry is in the same range as ESPR (98) in the Biotechnology industry. This means that ZOMDF’s stock grew similarly to ESPR’s over the last 12 months.

ZOMDF's Price Growth Rating (95) in the Pharmaceuticals Major industry is in the same range as ESPR (97) in the Biotechnology industry. This means that ZOMDF’s stock grew similarly to ESPR’s over the last 12 months.

ZOMDF's P/E Growth Rating (100) in the Pharmaceuticals Major industry is in the same range as ESPR (100) in the Biotechnology industry. This means that ZOMDF’s stock grew similarly to ESPR’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ESPRZOMDF
RSI
ODDS (%)
Bullish Trend 2 days ago
82%
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
70%
Momentum
ODDS (%)
Bearish Trend 2 days ago
85%
Bullish Trend 2 days ago
89%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 7 days ago
80%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
83%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
79%
Advances
ODDS (%)
Bullish Trend about 1 month ago
84%
Bullish Trend 14 days ago
81%
Declines
ODDS (%)
Bearish Trend 3 days ago
89%
Bearish Trend 10 days ago
83%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
83%
N/A
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
N/A
View a ticker or compare two or three
Ad is loading...
ESPR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ZOMDF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MSFJX18.32N/A
N/A
MFS Total Return R4
GPSCX7.97N/A
N/A
Victory RS Small Cap Equity A
DRDIX24.23N/A
N/A
Dearborn Partners Rising Dividend I
HOOSX25.76N/A
N/A
Hartford Schroders US Small Cap Opps R4
FHOFX21.07N/A
N/A
Fidelity Series Large Cp Grwth Idx

ESPR and

Correlation & Price change

A.I.dvisor tells us that ESPR and ALKS have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ESPR and ALKS's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ESPR
1D Price
Change %
ESPR100%
+9.12%
ALKS - ESPR
32%
Poorly correlated
+0.41%
PTPI - ESPR
29%
Poorly correlated
+28.10%
DVAX - ESPR
27%
Poorly correlated
+2.68%
ZOMDF - ESPR
26%
Poorly correlated
+0.38%
EVO - ESPR
26%
Poorly correlated
+10.89%
More

ZOMDF and

Correlation & Price change

A.I.dvisor indicates that over the last year, ZOMDF has been loosely correlated with SNDL. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if ZOMDF jumps, then SNDL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ZOMDF
1D Price
Change %
ZOMDF100%
+0.38%
SNDL - ZOMDF
38%
Loosely correlated
+2.21%
CDNA - ZOMDF
30%
Poorly correlated
+4.93%
EBS - ZOMDF
29%
Poorly correlated
+3.96%
ARAY - ZOMDF
29%
Poorly correlated
+4.83%
BNR - ZOMDF
28%
Poorly correlated
+1.22%
More